UY26885A1 - Activadores de la tetrazolil-fenil acetamido glucoquinasa - Google Patents

Activadores de la tetrazolil-fenil acetamido glucoquinasa

Info

Publication number
UY26885A1
UY26885A1 UY26885A UY26885A UY26885A1 UY 26885 A1 UY26885 A1 UY 26885A1 UY 26885 A UY26885 A UY 26885A UY 26885 A UY26885 A UY 26885A UY 26885 A1 UY26885 A1 UY 26885A1
Authority
UY
Uruguay
Prior art keywords
activators
glucoquinasa
tetrazolil
phenyl acetamido
phenyl
Prior art date
Application number
UY26885A
Other languages
English (en)
Spanish (es)
Inventor
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY26885A1 publication Critical patent/UY26885A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY26885A 2000-08-15 2001-08-14 Activadores de la tetrazolil-fenil acetamido glucoquinasa UY26885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15

Publications (1)

Publication Number Publication Date
UY26885A1 true UY26885A1 (es) 2002-02-28

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26885A UY26885A1 (es) 2000-08-15 2001-08-14 Activadores de la tetrazolil-fenil acetamido glucoquinasa

Country Status (20)

Country Link
US (3) US6369232B1 (OSRAM)
EP (1) EP1311504B1 (OSRAM)
JP (1) JP3961948B2 (OSRAM)
KR (1) KR100518061B1 (OSRAM)
CN (1) CN1209362C (OSRAM)
AR (1) AR031718A1 (OSRAM)
AT (1) ATE297921T1 (OSRAM)
AU (2) AU8399801A (OSRAM)
BR (1) BR0113312A (OSRAM)
CA (1) CA2419416C (OSRAM)
DE (1) DE60111540T2 (OSRAM)
DK (1) DK1311504T3 (OSRAM)
ES (1) ES2243541T3 (OSRAM)
MX (1) MXPA03001275A (OSRAM)
PA (1) PA8525201A1 (OSRAM)
PE (1) PE20020386A1 (OSRAM)
PT (1) PT1311504E (OSRAM)
UY (1) UY26885A1 (OSRAM)
WO (1) WO2002014312A1 (OSRAM)
ZA (1) ZA200300904B (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
RU2005113713A (ru) * 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PE20040801A1 (es) 2002-12-12 2004-11-25 Hoffmann La Roche Derivados de pirazina y piridina 5-sustituidos como activadores de glucoquinasa
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
JP2007530631A (ja) 2004-04-02 2007-11-01 ノバルティス アクチエンゲゼルシャフト チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法
CA2560689C (en) 2004-04-02 2011-03-01 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
TWI359149B (en) 2005-07-11 2012-03-01 Mitsubishi Tanabe Pharma Corp An oxime derivative and preparations thereof
JPWO2007026761A1 (ja) 2005-08-31 2009-03-12 アステラス製薬株式会社 チアゾール誘導体
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
BRPI0618062A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
ES2381864T3 (es) * 2005-12-15 2012-06-01 Nihon Nohyaku Co., Ltd. Derivado de ftalamida, pesticida agrícola u hortícola y utilización del pesticida
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5386350B2 (ja) * 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivative
EP2116533B1 (en) 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
WO2009047798A2 (en) * 2007-10-08 2009-04-16 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
US8329707B2 (en) 2008-01-18 2012-12-11 Astellas Pharma Inc. Substituted pyrazine compounds
HUE025224T2 (en) 2008-04-28 2016-02-29 Kyorin Seiyaku Kk Ciklopentilakrilsav amide derivatives
EP3199623B1 (en) 2010-03-31 2021-07-28 The Scripps Research Institute Reprogramming cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
AU728812B2 (en) * 1997-01-28 2001-01-18 Merck & Co., Inc. Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
ES2226811T3 (es) * 1999-03-29 2005-04-01 F. Hoffmann-La Roche Ag Activadores de glucoquinasa.

Also Published As

Publication number Publication date
BR0113312A (pt) 2003-07-01
CN1466584A (zh) 2004-01-07
EP1311504A1 (en) 2003-05-21
PT1311504E (pt) 2005-10-31
JP2004506632A (ja) 2004-03-04
DE60111540D1 (de) 2005-07-21
US20020035267A1 (en) 2002-03-21
DE60111540T2 (de) 2006-03-16
JP3961948B2 (ja) 2007-08-22
MXPA03001275A (es) 2003-06-30
US6388088B1 (en) 2002-05-14
ZA200300904B (en) 2004-04-30
PA8525201A1 (es) 2002-07-30
DK1311504T3 (da) 2005-10-17
WO2002014312A1 (en) 2002-02-21
CN1209362C (zh) 2005-07-06
EP1311504B1 (en) 2005-06-15
CA2419416C (en) 2009-10-13
ATE297921T1 (de) 2005-07-15
ES2243541T3 (es) 2005-12-01
AU8399801A (en) 2002-02-25
CA2419416A1 (en) 2002-02-21
AU2001283998B2 (en) 2005-10-20
PE20020386A1 (es) 2002-05-13
KR100518061B1 (ko) 2005-09-28
AR031718A1 (es) 2003-10-01
US6369232B1 (en) 2002-04-09
US20020065275A1 (en) 2002-05-30
KR20030022408A (ko) 2003-03-15
US20020035266A1 (en) 2002-03-21
US6441180B1 (en) 2002-08-27

Similar Documents

Publication Publication Date Title
UY26885A1 (es) Activadores de la tetrazolil-fenil acetamido glucoquinasa
ECSP014054A (es) Activadores de glucoquinasa alquinil fenil heteroaromatica
ECSP014067A (es) Activadores de fenil glucoquinasa para-aril o heterociclico sustituida
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
DK1349856T3 (da) Isoindolin-1-on-glucokinase-aktivatorer
ECSP045382A (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
ECSP014055A (es) Activadores de glucoquinasa que contienen hidantoina
UY26695A1 (es) Activadores para amino sustituidos de la fenilamida glucoquinasa
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
ATE412387T1 (de) Medizinische vorrichtungen
UA90460C2 (ru) Фармацевтический препарат, который включает антитело против рецептора egf
MY142777A (en) Substituted indole-o-glucosides
UA87991C2 (en) Substituted indole-o-glucosides
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
BRPI0607351A2 (pt) métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20
CY1114254T1 (el) Ενδοφλεβια ενεση μη νευροτοξικων ενεργοποιητων του πλασμινογονου για την αντιμετωπιση του εγκεφαλικου επεισοδιου
CR8009A (es) Compuestos benzo[1,2,5] tiadiazoles
UY26690A1 (es) Activadores heteroaromáticos de la alquinil - fenil glucoquinasa
BRPI0510407A (pt) derivados de 3-amino-2-fenilpirrolidina
WO2003070177A3 (en) Use of melatonin analogues for induction of general anesthesia
ECSP034651A (es) Activadores de glucocinasa isoindolin-1-ona
UY26080A1 (es) Nuevas dihidropirimidinas
PA8612101A1 (es) Composicion y procedimiento de tratamiento del platanero
UY27766A1 (es) Combinacion de insulina y un derivado de tiazolidindiona y uso de la misma para tratar la diabetes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140917